The COVIDHELP study will prospectively evaluate the yet unknown clinical course of the COVID-19 infection in cancer patients and document the impact of potential infrastructural limitations on cancer care of COVID-19 positive patients. All patients consenting will provide peripheral blood samples for prospective biobanking with the aim of investigating immune response and immunity against COVID-19.
Based on patients, who are treated in the University Cancer Center Hamburg (UCCH) and its
contracted partner network, which comprises all cancer treating departments at the University
Medical Center of Hamburg-Eppendorf (UKE), as well as 19 office-based oncologists and 20
surrounding hospitals, recruitment for the study will be done as follows:
(i) as a cancer patient during regular aftercare appointments who reports a current or past
COVID-19 infection.
(ii) as an acute COVID-19 patient who reports a prevalent cancer diagnosis
Data will be collected as available from routine clinical care and includes demographic and
biometric data, medical history, baseline data at inclusion as well as inpatient and
intensive care unit admissions. Upon consent, patients will provide peripheral blood samples
at time of inclusion and after 6 month. Recruitment is limited to a one-year period (April
2020 - April 2021).
Other: No Intervention
No Intervention
Key inclusion criteria:
- Known diagnosis of cancer
- Known diagnosis of CoVID-19 infection
- Age ≥ 18 years
- Signed informed consent
Key exclusion criteria:
• refusal of participation
University Hospital Hamburg Eppendorf
Hamburg, Germany
Investigator: S Guengoer
s.guengoer@uke.de
Investigator: Katja Weisel, MD
Katja Weisel, MD
+49407410 - 58787
k.weisel@uke.de
Niklas Boerschel, MD
+49407410 - 51410
n.boerschel@uke.de
Katja Weisel, MD, Principal Investigator
University Medical Center of Hamburg-Eppendorf